COVID-19 pneumonia
ICD-10 J12.8 · ICD-11 RA01.0/CA40.1

Treatment of Severe Noncritical COVID-19 Pneumonia in Hospitalized Patients (SpO2 ≤94%)

This protocol applies to hospitalized adults with COVID-19 pneumonia who are severely hypoxic but have not yet progressed to critical illness. The clinical picture sits below the threshold for mechanical ventilation or ECMO yet requires escalated inpatient management.

Clinical Scenario SpO2 ≤94% on room air — including patients already on low-flow supplemental oxygen — who are not on mechanical ventilation or ECMO.

Treatment Approach

Current evidence-based guidance for this population combines corticosteroids with an additional targeted anti-inflammatory agent — either from the interleukin-6 inhibitor class or the Janus kinase inhibitor class. Agent selection, alternatives, sequencing, and clinical decision criteria are detailed in the full structured regimen below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/cid/ciac724

Among hospitalized patients with severe, but noncritical, COVID-19, the IDSA guideline panel suggests dexamethasone rather than no dexamethasone.

Severe illness is defined as patients with SpO2 ≤94% on room air, including patients on supplemental oxygen.

Among hospitalized adults with progressive severe or critical COVID-19 who have elevated markers of systemic inflammation, the IDSA guideline panel suggests tocilizumab in addition to standard of care (ie, steroids) rather than standard of care alone.

When tocilizumab is not available, for patients who would otherwise qualify for tocilizumab, the IDSA guideline panel suggests sarilumab in addition to standard of care (ie, steroids) rather than standard of care alone.

Among hospitalized adults with severe COVID-19, the IDSA panel suggests baricitinib with corticosteroids rather than no baricitinib.

Among hospitalized adults with severe COVID-19 but not on noninvasive or invasive mechanical ventilation, the IDSA panel suggests tofacitinib rather than no tofacitinib.

View source ↗